Understanding HIV phenotypic resistance testing: Usefulness in managing treatment-experienced patients

AIDS Reviews

Volumn 11, Issue 4, 2009, Pages 223-230

  MacArthur, Rodger D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Darunavir; Genotype; HIV; Phenotype; Resistance; Tipranavir

Indexed keywords

ABACAVIR; AMPRENAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG SENSITIVITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; LINEAR REGRESSION ANALYSIS; NONHUMAN; PATIENT CARE; PHENOTYPE; PRACTICE GUIDELINE; REVIEW; TREATMENT RESPONSE; VALIDATION STUDY; VIRUS ISOLATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 74249117632     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. [Accessed December 2, 2008].
2. Cooper D, Gatell J, Rockstroh J, et al.; BENCHMRK-1 Study Group. 48-week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1. 15th CROI. February 2008; Boston, USA [poster 788].
3. Steigbigel R, Kumar P, Eron J, et al.; BENCHMRK-2 Study Group. 48-week results from BENCHMRK-2, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1. 15th CROI. February 2008. Boston, USA [poster 789].
4. Haubrich R, Cahn P, Grinsztejn B, et al.; the DUET-1 study group. DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. 15th CROI. February 2008. Boston, USA [poster 790].
5. Johnson M, Campbell T, Clotet B, et al.; the DUET-2 study group. DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. 15th CROI. February 2008. Boston, USA [poster 791].
6. Perez-Elias M, Garcia-Arota I, Muñoz V, et al.; Realvirfen study group. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther. 2003;8:577-84.
7. MacArthur R. An updated guide to genotype interpretation. AIDS Reader. 2004;14:256-66.
8. Qari S, Respess R, Weinstock H, et al. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol. 2002;40:31-5.
9. Ross L, Boulmé R, Fisher R, et al. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res Hum Retroviruses. 2005;21:933-9.
10. Schmidt B, Walter H, Zeitler N, Korn K. Genotypic drug resistance interpretation systems- the cutting edge of antiretroviral therapy. AIDS Rev. 2002;4:148-56.
11. King M, Rode R, Cohen-Codar I, et al. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2007;51:3067-74.
12. Costagliola D, Cozzi-Lepri A, Dalban C, Cheng B. The Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Initiatives for developing and comparing genotype interpretation systems step 1: external validation of existing rules-based algorithm for abacavir and ddI evaluated on virological response. Antivir Ther. 2005;10(Suppl 1):S11 [abstract 9].
13. Sturmer M, Doerr H, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther. 2003;8:239-44.
14. Baxter J, Schapiro J, Boucher C, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol. 2006;80:10794-801.
15. Scherer J, Boucher C, Baxter J, Schapiro J, Kohlbrenner V, Hall D. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score. 11th European AIDS Conference. October 2007; Madrid, Spain [poster P3.4/07].
16. Schapiro J, Scherer J, Vinisko R, et al. Genotypic tipranavir scores as predictors of response. 11th European AIDS Conference. October 2007. Madrid, Spain [poster P3.4/16].
17. Yazdanpanah Y, Vray M, Meynard J, et al. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007;8:439-50.
18. Katzenstein D, Bosch R, Hellmann N, Wang N, Bacheler L, Albrecht M; ACTG 364 Study Team. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003;17:821-30.
19. Vray M, Meynard J, Dalban C, et al.; Narval Trial Group. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing geno-typing, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther. 2003;8:427-34.
20. Loutfy M, Raboud J, Walmsley S, et al. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther. 2004;9: 595-602.
21. Ciancio B, Trotta M, Lorenzini P, et al. The effect of number of mutations and of drugclass sparing on virological response to salvage genotypeguided antiretroviral therapy. Antivir Ther. 2003;8:611-6.
22. Haupts S, Ledergerber B, Böni J, et al.; Swiss HIV Cohort Study. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir Ther. 2003;8:443-54.
23. Baxter J, Mayers D, Wentworth D, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000; 14:F83-93.
24. Tural C, Ruiz L, Holtzer C, et al.; Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16: 209-18.
25. Zhang J, Rhee S, Taylor J, Shafer R. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense. HIV drug susceptibility assay. J Acquir Immune Defic Syndr. 2005;38:439-44.
26. Wang K, Samudrala R, Mittler J. Antivirogram or phenosense: a comparison of their reproducibility and an analysis of their correlation. Antivir Ther. 2004;9:703-12.
27. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P; Virco Clinical Response Collaborative Team. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007;145:47-55.
28. Winters B, Montaner J, Harrigan P, et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr. 2008;48:26-34.
29. Virco. VircoTYPE: How does it work? Available at: http://www.vircolab. com/productcenter/ vircotype-hiv-1/how-does-vircotype-work [accessed September 11, 2009].
30. Wang K, Jenwitheesuk E, Samudrala R, Mittler J. Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance. Antivir Ther. 2004;9:343-52.
31. Swanstrom R, Bosch R, Katzenstein D, et al.; AIDS Clinical Trials Group Protocol 359 Team. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis. 2004;190:886-93.
32. Van Craenenbroeck E, Vermeiren H, Muyldermans G, et al. Prediction of HIV-1 drug susceptibility phenotype from viral genotype using linear regression modeling. 4th European HIV Drug Resistance Workshop. March 2006. Monte Carlo, Monaco [poster 60].
33. van Houtte M, Picchio G, Van der Borght K, et al. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol. 2009;81: 1702-9.
34. Bacheler L, Vermeiren H, Winters B, et al. Clinically relevant phenotypic resistance and cross resistance to tipranavir among recent routine clinical isolates. 4th European HIV Drug Resistance Workshop. March 2006. Monte Carlo, Monaco [poster 40].
35. Coakley E, Chappey C, Flandre P, et al. Defining lower (L) and upper (U) phenotypic clinical cutoffs (CCO's) for tipranavir/r (TPV), lopinavir/r (LPV), saquinavir (SQV) and amprenavir (APV) co-administered with ritonavir (r) within the RESIST dataset by the PhenoSense assay. 46th Annual ICAAC. September 2006. San Francisco, USA [abstract H-995].
36. Coakley E, Chappey C, Flandre P, et al. Defining lower and upper phenotypic clinical cutoffs for tipranavir, lopinavir, saquinavir and amprenavir co-administered with ritonavir within the RESIST dataset using the PhenoSense assay (Monogram Biosciences). Antivir Ther. 2006;11:S81 [abstract 71].
37. Winters B, Vermeiren H, Van Craenenbroeck, et al. Development of VircoTYPE resistance analysis, including clinical cut-offs, for TMC 114. Antivir Ther. 2006;11:S180 [abstract 160].
38. Staes M, Van Craenenbroeck E, Vermeiren H, et al. Analyses of susceptibility and cross-resistance between TMC114 and other protease inhibitors among >56,000 routine samples, using linear regression model-based fold change predictors. Antivir Ther. 2006;11:S33 [abstract 28].
39. Picchio G, Staes M, Van Craenenbroeck E, et al. HIV-1 susceptibility to TMC114 among routine clinical samples with different levels of protease inhibitor susceptibility using linear regression model-based fold change predictions. 46th ICAAC. September 2006. San Francisco, USA [abstract H999].
40. Coakley E, Chappey C, Benhamida J, Picchio G, de Béthune M. Defining the upper and lower phenotypic clinical cut-offs for darunavir/ritonavir by the PhenoSense assay. 14th CROI. February 2007. Los Angeles, USA [poster 610].